ISSN: 1859 - 2872
Adverse effects of first-line treatment with afatinib in patients with advanced non-small cell lung cancer
Main Article Content
Keywords
Abstract
Background: Currently, detailed analyses of adverse events (AE) of Afatinib in the treatment of patients with non-small cell lung cancer (NSCLC) are limited. The objective of this study was to evaluate AE in patients with advanced stage NSCLC treated by Afatinib as first-line treatment. Methods: A retrospective study of 74 patients with advanced stage NSCLC harboring EGFR mutations, treated with Afatinib as first-line treatment, and monthly monitoring and assessment of AE. The primary endpoints were AE and their association with clinical and treatment characteristics. Result: The mean age of patients was 61.5 years, with 70.3% male and 64.9% having a history of smoking. 67.6% of patients were started at 30 mg and 32.4% received 40 mg. The tolerated dose of 40 mg was reduced to 14.9% and 6 patients could only be treated with a dose of 20 mg, 77% of patients tolerating a dose of 30 mg. AE occurred in 77% of patients, mainly rash at 68.9%, followed by diarrhea at 43.2%, paronychia and stomatitis at 23% and 6.8%, respectively. Most AE were grade 1 and 2. 23% of patients had to reduce the dose due to drug toxicity. Patients with a starting dose of 40 mg tended to experience more AE than those treated with 30 mg, at rates of 83.3% and 76%, respectively (p = 0.47). There was no association between AE and gender, smoking status or treatment’s dose. Conclusion: Treatment by Afatinib has a high rate of patients experiencing adverse effects, however, most of them were grade 1 and grade 2. There was no association between adverse events and some clinical and treatment characteristics of the patients.
Article Details
References
2. Sequist LV, Yang JC, Yamamoto N et al (2013 Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations (LUX-Lung 3): An open-label, randomised controlled trial. Lancet Oncol 14(6): 553-561.
3. Wu YL, Zhou C, Hu CP et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced NSCLC harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol 15(2): 213-222.
4. Pham CP, Nguyen TTH, Do AT et al (2024) A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam. BMC Cancer 24(1): 1-10. doi:10.1186/S12885-024-11891-W/TABLES/5.
5. Ho GF, Chai CS, Alip A et al (2019) Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: A multicenter observational study. BMC Cancer 19: 896.
6. Molassiotis A, Wang CY, Ho C et al (2020) Nurse-led interventions for the management of cancer treatment-related symptoms in patients with lung cancer: A systematic review and meta-analysis. Support Care Cancer 28(6): 2541-2550.
7. Kudialis A, Williams GR (2019) Oncology nurse’s role in patient management with oral targeted therapies. Clin J Oncol Nurs 23(2):185-192.
8. Verbrugghe M, Verhaeghe S, Lauwaert K et al (2013) Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: A systematic review. Cancer Treat Rev 39(6): 610-621.
9. Luan PV, Tien ND, Hai NM et al (2021) Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations. Ther Adv Med Oncol 13. doi:10.1177/1758835921992977.
10. Nguyễn Thị Như Hoa, Lê Văn Quảng, Đỗ Hùng Kiên (2023) Kết quả bước đầu điều trị Osimertinib trong ung thư phổi không tế bào nhỏ giai đoạn muộn có đột biến gen EGFR, Tạp chí Y học lâm sàng Bệnh viện Trung ương Huế, 2023; Số 91: 70 – 75. DOI: 10.38103/jcmhch.91.12.
11. https://www.boehringerone.com/sites/default/ files/pdfs/vn/Boehringer_Giotrif-HCPs-Handbook-May-15_2018.pdf.
12. National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017.
13. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6): 649-655.
14. Chen YC, Tsai MJ, Lee MH et al (2021) Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations. BMC Cancer 21(1). doi:10.1186/S12885-021-08235-3.
15. Tu CY, Chen CM, Liao WC et al (2018) Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations. Oncotarget 9(36): 24237-24247.
Article Sidebar
